Skip to main content
Premium Trial:

Request an Annual Quote

Genialis Inks Data Partnerships with Sidra Medicine, Sapien Biosciences

NEW YORK – Genialis said on Wednesday that it has entered into data partnerships with Sidra Medicine of Qatar and Sapien Biosciences of India.

The partnerships provide the RNA biomarker firm with new datasets representing patients from Qatar, India, and Asia more broadly. In a statement, Genialis said the data would help it validate biomarkers on diverse patient populations "to better predict responses to KRAS inhibitors, immunotherapies, and other emerging classes of therapeutics."

"Sidra Medicine is committed to enhancing its research and pediatric cancer care program as part of our mission to provide precision medicine for all our patients in Qatar," Wouter Hendrickx, lead PI of the Precision Oncology Initiative at Sidra Medicine, said in a statement. "By integrating Genialis' suite of predictive biomarker algorithms into our workflows, we can begin to truly understand the molecular diversity of our patients and personalize treatment protocols and therapies."

Genialis, based in Ljubljana, Slovenia and Boston, has been developing RNA biomarker models for use in cancer diagnostics and drug discovery. It announced $13 million in Series A funding in March 2023 and a partnership with Cancer Research UK and Cancer Research Horizons to validate its therapy response prediction model last October.

"Through these new data partnerships, we can incorporate data from all over the world into our modeling process," Genialis CEO Rafael Rosengarten said in a statement. "We're confident this will help us ​​deliver biomarkers that work for real patients and hopefully begin to close the gap in healthcare outcomes."